The here-reported ability of low amounts of CyaA to effectively limit the increase of iron acquisition capacities of CD11b/CD18-expressing myeloid cells opens an intriguing opportunity to explore the potential of CyaA for the treatment of myelomas. Here, ITGB2 is linked to plasma cell myeloma.